<DOC>
	<DOCNO>NCT00174707</DOCNO>
	<brief_summary>Primary objective : - To compare disease free survival ( DFS ) patient treat sequential epidoxorubicin , cyclophosphamide , methotrexate , fluorouracil ( CMF ) regimen patient treat treatment plus docetaxel give sequentially epidoxorubicin Secondary objective : - To compare DFS patient treat sequential epidoxorubicin , docetaxel CMF ( patient &gt; = 4 lymph node ) regimen patient treat sequential intensified epidoxorubicin/docetaxel/high dose ( HD ) cyclophosphamide regimen - To evaluate overall survival arm - To evaluate tolerability sequential intensified epidoxorubicin/docetaxel/HD-cyclophosphamide ( arm C ) - To compare safety sequential epidoxorubicin/docetaxel/CMF ( arm B ) regimen versus standard sequential epidoxorubicin/CMF regimen ( arm A )</brief_summary>
	<brief_title>Study Docetaxel Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Inclusion criterion : Histologically proven breast cancer first diagnosis &gt; = 4 axillary node show evidence tumor among minimum 10 resect lymph node ( American Joint Committee Cancer 1992 pathologic stag pT14 , pN12 [ least 1/10 ] , M0 ) Ages ≥ 18 year ≤ 70 year patient randomize arm A B. Ages ≥ 18 year ≤ 65 year patient randomize arm C World Health Organization performance status 01 Definitive surgical treatment must either mastectomy breast conserving surgery , axillary lymph node dissection operable breast cancer ( clinical T13 , N1 , M0 ) . Margins resect specimen definitive surgery must histologically free invasive adenocarcinoma ductal carcinoma situ . Lobular carcinoma situ count positive margin . Patients histologicallydocumented infiltration skin ( pT4a ) also eligible Surgical procedure complete within 8 week randomization . Laboratory requirement : Hematology : Neutrophils ≥ 2 x 10^9/L Platelets ≥ 100 x 10^9/L Hemoglobin ≥ 10 g/DL Hepatic function : Total bilirubin ≤ 1 time uppernormal limit institutional normal value . ASAT &amp; ALAT ≤ 2.5 UNL , alkaline phosphatase ≤ 5 UNL . Patients ASAT &amp; /or ALAT &gt; 1.5 x UNL associate alkaline phosphatase &gt; 2.5 x UNL eligible study Renal function : Creatinine ≤ 140 µmol/L ( 1.6 mg/DL ) ; limit value , creatinine clearance perform ≥ 60 ml/min Normal leave ventricular ejection fraction superior low limit institution Patients must accessible treatment followup . Patients register trial must treat follow participate center Complete workup within 3 month prior randomization . All patient bilateral mammography , chest X ray ( posteroanterior [ PA ] lateral ) , abdominal ultrasound and/or compute tomography scan , &amp; bone scan Exclusion criterion : Axillary lymph node free involvement Primary breast cancer histology adenocarcinoma Inflammatory carcinoma Any locally advance ( T4 and/or N2known N3 ) metastatic ( M1 ) breast cancer Past current history ipsilateral contralateral invasive contralateral ductal situ breast carcinoma . A past current history ipsilateral ductal situ lobular situ ( ipsilateral contralateral ) breast carcinoma exclusion criterion Histologically positive resection margin . Patients undergo conservative resection margin consider eligible radically resect within 4 week randomization Pregnant lactate woman woman childbearing potential ( e.g . use adequate contraception ) History prior concomitant malignancy curatively treat basal cell skin cancer excise cervical carcinoma situ Symptomatic peripheral neuropathy &gt; grade 2 accord National Cancer Institute Common Toxicity Criteria Other serious illness medical condition : Congestive heart failure angina pectoris even medically control . Previous history myocardial infarction within 1 year study entry , uncontrolled high risk hypertension arrhythmia History significant neurologic psychiatric disorder include dementia seizure Active infection Peptic ulcer , unstable diabetes mellitus contraindication use dexamethasone Concurrent treatment experimental drug . Participation another clinical trial investigational regimen within 30 day prior study entry Concurrent treatment anticancer therapy Concurrent treatment ovarian hormonal replacement therapy . Prior treatment stop study entry Prior systemic anticancer therapy breast cancer ( chemotherapy , hormonal therapy , immunotherapy , etc . ) adjuvant and/or neoadjuvant therapy Concomitant treatment corticosteroid use reason premedication ; however , patient receive chronic treatment corticosteroid ( &gt; 6 month ) low dose ( ≤ 20 mg methylprednisolone equivalent dose corticosteroid ) whichever reason eligible Definite contraindication use corticosteroid premedication Prior radiation therapy The information intend contain consideration relevant patient 's potential participation clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>